Loading…
← CockpitCompetitor Analysis › LXRX Lexicon Pharmaceuticals, Inc.Open in the cockpit ↗

Lexicon Pharmaceuticals, Inc.LXRXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum weak 34
Mkt cap
$766M
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$3.68M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-121.9 pp
WACC 10.2%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · USD$1.72
1D-3.4%
1W-8.0%
1M+8.9%
3M-21.1%
6M-22.2%
YTD+49.6%
1Y+17.8%
ATR %6.3%
Beta1.00
52w lowhigh35.8% off high

What Lexicon Pharmaceuticals does

Employees: 81

Lexicon Pharmaceuticals at a glance

Size Lexicon Pharmaceuticals (LXRX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $766M, the 2402nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $1.72 on 18 Nov 2026.

Performance Over six months the shares fell 22.2%, against -7.0% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 45.6% over the last twelve months (peer median +3.5%); the operating margin is -147.4% (peer median 12.0%).

Valuation It trades at 16.7× enterprise value to sales against a peer median of 2.5× (2nd most expensive of 18).

Capital Return on invested capital runs 121.9 points below its cost of capital (10.2% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 94LXRX 77
Six months, rebased to 100: Lexicon Pharmaceuticals against the median of its 20 peers (local-currency closes).

Lexicon Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$38.5M$49.8M$31.1M$1.20M$139,000
Revenue growth—+60%+2,481%+766%—
Gross profit$37.7M$48.9M$29.9M$565,000-$288,000
EBITDA-$56.4M-$48.3M-$184M-$171M-$100M
Net income-$62.4M-$50.3M-$200M-$177M-$102M
Free cash flow-$49.2M-$67.9M-$181M-$162M-$90.2M
Capital expenditure$0$0$1.03M$470,000$1.33M
Total debt$59.5M$62.2M$106M$106M$55.3M

Quarterly statements and history in the cockpit →

Lexicon Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%3001002390002424BLISSGVS0029072171000411ARDX600479IRWDGUDORIC2186SANOFIRIGL688073LXRX6-month return →1-month return →
Up and to the right = strong over both horizons. Lexicon Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×10×20×30×3001002390002424BLISSGVS0029072171000411ARDX600479IRWDGUDSANOFILXRXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lexicon Pharmaceuticals is the large dot.

Lexicon Pharmaceuticals competitors and peer comparison

How Lexicon Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lexicon Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureLXRXPeer medianRank in peer set
1-month return+8.9%-6.5%4th highest of 19
6-month return-22.2%-7.0%4th lowest of 19
Distance from 52-week high-35.8%-32.6%7th lowest of 19
Revenue growth (TTM)-45.6%+3.5%lowest of 19
Operating margin-147.4%12.0%2nd lowest of 19
EV / Sales16.7×2.5×2nd most expensive of 18
ROIC minus cost of capital-121.9 pp+1.9 pp2nd lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Hunan Jiudian Pharmaceutical 300705.SZChina$738M-20%-5%13%1.8×-2.0%+26.1%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Luye Pharma 2186.HKHong Kong$736M-32%+3%18%1.1×-11.8%+1.9%
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%

Questions

Which companies are Lexicon Pharmaceuticals's closest peers?
The cockpit's peer set: Katakura Industries (3001.T), Guizhou Xinbang Pharmaceutical (002390.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ), Bliss GVS Pharma (BLISSGVS.NS), Sichuan Neautus Traditional Chinese (2206.HK), Chongqing Pharscin Pharmaceutical (002907.SZ), CARsgen Therapeutics (2171.HK), Zhejiang Int'l (000411.SZ).
Is Lexicon Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 16.7× against a peer median of 2.5×, 2nd most expensive of 18 in its peer set.
How has Lexicon Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -22.2% against -7.0% for the median peer; over one year +17.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.